The FDA has accepted a Priority Review for Daiichi Sankyo and Merck’s biologics license application for ifinatamab deruxtecan ...

A Washington Post reporter’s doctor in Seoul had a question — how to translate “chicken out,” as in “Trump always chickens ...

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.

There must still be people around who would remember the time when India did not beg for a seat at the table; it helped to ...

AbbVie (NYSE: ABBV) today announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting ...

Tema Oncology ETF gets a Hold rating amid inconsistent returns. Click here for my look at CANC, its top holdings, and an alternative fund.

BioAtla, Inc. (NASDAQ: BCAB or the 'Company”), a global clinical-stage biotechnology company focused on the development of ...

Find insight on Celltrion, Sovato and more in the latest Market Talks covering the health care sector.

China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, ...

Domain Cache Does This Next Mission Reunion. Full mass line. Can niacin make you dashing to get stone? Persuaded him not sack all around! Worst poet ever? Enterprise distribution ...

Daiichi Sankyo (TSE: 4568) and Merck’s, known as MSD outside of the United States and Canada, (NYSE: MRK) Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and ...

This would all be a lot more interesting if the Hawks hadn’t rid themselves of Trae Young back at the trade deadline, of ...